Skip to main content
SpringerLink
Log in

Urologika

  • Chapter
Arzneiverordnungs-Report 2006

  • 419 Accesses

Auszug

Mit fast 70 Prozent der Verordnungen stellen die Prostatamittel nach wie vor die überwiegende Gruppe der Urologika dar. Urologische Antiinfektiva, Urolithiasismittel, Phosphatbinder und Kathetermittel erreichen nur kleine Verordnungszahlen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abrams P, Freeman R, Anderström C, Mattiasson A (1998): Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81: 801–810.

    PubMed  CAS  Google Scholar 

  • Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D et al (1999): A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: 694–701.

    PubMed  CAS  Google Scholar 

  • Boyle P, Gould AL, Roehrborn CG (1996): Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48: 398–405.

    Article  PubMed  CAS  Google Scholar 

  • Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ et al (1998): Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA 280: 1995–2000.

    Article  PubMed  CAS  Google Scholar 

  • Chapple CR (1996): Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 29: 129–144.

    PubMed  CAS  Google Scholar 

  • Chapple CR (2000): Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(5A Suppl.): 33–46.

    Article  PubMed  CAS  Google Scholar 

  • Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group (2004): Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Brit J Urol Int. 93: 303–310.

    CAS  Google Scholar 

  • Djavan B, Marberger M (1999). A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1–13.

    Article  PubMed  CAS  Google Scholar 

  • Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S (1999): Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 10: 283–289.

    Article  CAS  Google Scholar 

  • European Medicines Agency (EMEA) (2004): Ausschuss für Humanarzneimittel. Europäischer Bewertungsbericht (EPAR) Emselex. Im Internet: http://www.emea.eu.int/humandocs/HUMANS/EPAR/emselex/emselex.htm

    Google Scholar 

  • Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC (1998): 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 160: 12–16.

    Article  PubMed  CAS  Google Scholar 

  • Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G (1995): Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 288: 201–207.

    Article  PubMed  CAS  Google Scholar 

  • Guay DRP (1999): Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy 19: 267–280.

    Article  PubMed  CAS  Google Scholar 

  • Haab F, Stewart L, Dwyer P (2004) Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45: 420–429.

    Article  PubMed  CAS  Google Scholar 

  • Harvey M-A, Baker K, Wells GA (2003): Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis. Am J Obstet Gynecol 185: 56–61.

    Article  Google Scholar 

  • Hay-Smith EJ, Bo Berghmans LC, Hendriks HJ, de Bie RA van Waalwijk van Doorn ES (2003): Pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst. Rev. 2003 (1): CD001407.

    Google Scholar 

  • Herbison P, Hay-Smith J, Ellis G, Moore K (2003): Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Brit Med J 326: 841–847.

    Article  PubMed  CAS  Google Scholar 

  • Hooton TM, Winter C, Tiu F, Stamm WE (1995): Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 273: 41–45.

    Article  PubMed  CAS  Google Scholar 

  • Iselin CE, Schmidlin F, Borst F, Rohner S, Graber P (1997): Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate. Brit J Urol 79: 915–919.

    PubMed  CAS  Google Scholar 

  • Janssen CCM, Lagro-Janssen ALM, Felling AJA (2003): The effects of physiotherapy for female urinary incontinence: individual compared with group treatment. Brit J Urol Int 87: 201–206.

    Google Scholar 

  • Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM (2005): Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 95: 81–85.

    Article  PubMed  Google Scholar 

  • Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB and the Prospective European Doxazosin and Combination Therapy Study Investigators (2003): Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PRE-DICT) trial. Urology 61: 119–126.

    Article  PubMed  Google Scholar 

  • Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M (2004): A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66: 1239–1247.

    Article  PubMed  CAS  Google Scholar 

  • McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM et al for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003): The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387–2398.

    Article  PubMed  CAS  Google Scholar 

  • McDowell BJ, Engberg S, Sereika S, Donovan N, Jubeck ME, Weber E, Engberg R (1999): Effectiveness of behavioral therapy to treat incontinence in homebound older adults. J Am Geriatr Soc 47: 309–318.

    PubMed  CAS  Google Scholar 

  • Milani S, Djavan B (2005): Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 95(Suppl 4): 29–36.

    Article  PubMed  CAS  Google Scholar 

  • Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC; Duloxetine UI Study Group. Duloxetine vs placebo in the treatment of stress urinary incontinence: a fourcontinent randomized clinical trial. Brit J Urol Int. 2004; 93: 311–318.

    CAS  Google Scholar 

  • Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M (1990): Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Brit J Urol 66: 479–485.

    PubMed  CAS  Google Scholar 

  • Ouslander JG, Blaustein J, Connor A, Pitt A (1988): Habit training and oxybutynin for incontinence in nursing home patients: a placebo-controlled trial. J Am Geriatr Soc 36: 40–46.

    PubMed  CAS  Google Scholar 

  • Ouslander JG, Schnelle JF, Uman G, Fingold S, Nigam JG et al (1995): Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 43: 610–617.

    PubMed  CAS  Google Scholar 

  • Riva D, Casolati E (1984): Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obst Gyn 11: 37–42.

    CAS  Google Scholar 

  • Roe B, Williams K, Palmer M (2003): Bladder training for uninary incontinence in adults (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.

    Google Scholar 

  • Stille W, Brodt HR, Groll AH, Just-Nübling G (2005): Antibiotika-Therapie in Klinik und Praxis der antiinfektiösen Behandlung. 11.Aufl., Schattauer, Stuttgart New York, S. 245–246.

    Google Scholar 

  • Stöhrer M, Bauer P, Giannetti BM, Richter R, Burgdörfer H, Mürtz G (1991): Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. Urol Int 47: 138–143.

    Article  PubMed  Google Scholar 

  • Subak LL, Quesenberry CP, Posner SF, Cattolica E, Soghikian K (2003): The effect of behavioral therapy on urinary incontinence: a randomized controlled trial. Obstet Gynecol 100: 72–78.

    Article  Google Scholar 

  • Szonyi G, Collas DM, Ding YY, Malone-Lee JG (1995): Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 24: 287–291.

    Article  PubMed  CAS  Google Scholar 

  • Tapp AJS, Cardozo LD, Versi E, Cooper D (1990): The treatment of detrusor instability in postmenopausal women with oxyxbutynin chloride: a double blind placebo controlled study. Brit J Obstet Gynaec 97: 521–526.

    PubMed  CAS  Google Scholar 

  • Thüroff JW, Bunke B, Ebner A, Faber P, de Geeter P et al (1991): Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145: 813–817.

    PubMed  Google Scholar 

  • Thüroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U et al (1998): Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 16(suppl): S48–S61.

    Article  PubMed  Google Scholar 

  • Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int J Urol. 2000; 7: 199–205.

    Article  PubMed  CAS  Google Scholar 

  • Uhari M, Nuutinen M, Turtinen J (1996): Adverse reactions in children during longterm antimicrobial therapy. Pediatr Infect Dis 15: 404–418.

    Article  CAS  Google Scholar 

  • Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE for the Infectious Diseases Society of America (IDSA) (1999): Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 29: 745–758.

    PubMed  CAS  Google Scholar 

  • Wehnert J, Sage S (1992): Therapie der Blaseninstabilität und Urge-Inkontinenz mit Propiverin hydrochlorid (Mictonorm®) und Oxybutyninchlorid (Dridase®) — eine randomisierte Cross-over-Vergleichsstudie. Akt Urol 23: 7–11.

    Article  Google Scholar 

  • Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2003; (1): CD002081.

    Google Scholar 

  • Wyman JF, Fantl JA, McClish DK, Bump RC (1998): Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol 179: 999–1007.

    Article  PubMed  CAS  Google Scholar 

  • Zorzitto ML, Holliday PJ, Jewett MAS, Herschorn S, Fernie GR (1989): Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 18: 195–200.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Pharmakologie, Zentralkrankenhaus Sankt-Jürgen-Straße, 28205, Bremen

    Prof. Dr. med. Bernd Mühlbauer

  2. Pharmakologisches Institut der Universität, Wilhelmstraße 56, 72074, Tübingen

    Prof. Dr. med. Hartmut Osswald

Authors
  1. Prof. Dr. med. Bernd Mühlbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Hartmut Osswald
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Mühlbauer, B., Osswald, H. (2007). Urologika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_47

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-34370-7_47

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-34369-1

  • Online ISBN: 978-3-540-34370-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation